Physician profile
Harold Mars
NPI 1003900812
$1,654.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $401.00 | 2019-2020 | |
| Emd Serono, INC. | $280.08 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $216.62 | 2019 | |
| Genzyme Corporation | $209.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $171.17 | 2019-2020 | |
| Biogen, INC. | $131.98 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $46.55 | 2019 | |
| Amgen INC. | $40.51 | 2019 | |
| Vertical Pharmaceuticals, LLC | $39.93 | 2019 | |
| Ucb, INC. | $23.23 | 2019 | |
| Kyowa Kirin, INC. | $17.86 | 2019 | |
| Lundbeck LLC | $17.55 | 2019 | |
| Acorda Therapeutics, INC | $16.42 | 2019 | |
| Tanabe Pharma America, INC. | $16.22 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $12.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Mars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.